Alligator Bioscience Ab

Aptevo Research and Development LLC

Aptevo Reserch and Development LLC

Peter Ellmark

Laura Von Schantz

Christina Furebring

Sara Fritzell

Laura Varas

Niina Veitonmaki

Per Norlen

Anna Sall

Eva Maria Dahlen

Lynda Misher

Gabriela Hernandez-Hoyos

David Bienvenue

Jessica Petersson

Karin Enell Smith

Danielle Mitchell

Ann-Christin Malmborg Hager

Karin Hagerbrand

Anna Säll

Karin Haraldsson

Mattias Levin

Angelica Loskog

Helena Persson

Fredrik Karlsson

Thomas Tötterman

Linda Sandin

Sara Mangsbo

Danielle Van Citters

Per Norlén

Niina Veitonmäki

Eva Dahlén

Per NORLÉN

Anna SÄLL

Eva DAHLÉN

Niina VEITONMÄKI

Marie Karlsson

The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).

Peptides

The present invention provides polypeptides capable of targeting antigens, such as neoantigens, to particular immune cells, and associated therapeutic methods. In particular embodiments, the polypeptides are antibodies or antibody-based polypeptides.

Methods and compositions

The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.

Bispecific polypeptides against CD137

The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.

Polypeptides

The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.

Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods

The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.

Anti-CD137 antibodies and uses thereof

Oncofetal antigen binding proteins and related compositions and methods

The present invention relates to combination therapies for treating a solid tumour in a subject. The combination therapies comprise (a) an antibody, or antigen-binding portion thereof, that specifically binds to CD40, and (b) a further immunotherapeutic agent with efficacy in the treatment of cancer, which agent is not an anti-CD40 antibody or antigen-binding fragment thereof. The invention also relates to a kits and methods of using such therapies.

Combination therapies with anti CD40 antibodies

The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same. The first and/or second T cell target may be selected from the group consisting of OX40, CTLA-4, CD137, CD27, GITR and CD28.

The invention provides an antibody or fragment thereof that specifically binds to human CD40.

Anti-CD40 antibodies

The invention provides libraries of antibody molecules, libraries of nucleic acids encoding antibody molecules, methods of producing said libraries, and methods of using said libraries to select an antibody which specifically binds to an antigen. The libraries of antibody molecules include a plurality of different antibody variable domains generated by creating diversity in the CDR regions.

scFV antibody library

Growing community of inventors

Lund, Sweden

Peter Ellmark